Estradiol vs Estriol (2026) Updated May 2026· 17d ago

Quick answer: Estradiol is the strongest estrogen and FDA-approved standard for hormone therapy (transdermal patch, oral, vaginal ring). Estriol is a weaker estrogen used primarily for vaginal atrophy — only available via compounding pharmacies in the US.

Clinically reviewed by Editorial Medical Review, MD, NAMS-CMP · Last updated 2026-05-22

How they work

Estradiol

Estradiol (E2) binds both ERα and ERβ receptors with high affinity. Primary estrogen of premenopausal years. Affects bone density, cardiovascular endothelium, brain thermoregulation, vaginal/urinary tissue, and breast.

Estriol

Estriol (E3) binds ERβ preferentially. ~80x weaker than estradiol at ERα. Limited systemic activity — primary effects on urogenital tissues. Dominant estrogen during pregnancy.

Available formulations

Estradiol

Transdermal patch (Climara, Vivelle-Dot) — preferred for VTE/stroke risk
Oral tablet (Estrace, generic) — convenient but first-pass liver
Vaginal ring (Estring, Femring) — local OR systemic dosing
Topical cream/gel (EstroGel, Divigel)
Vaginal cream (Estrace cream) — local atrophy treatment

Estriol

Vaginal cream — most common, compounded
Compounded oral capsules (rarely prescribed in US)
Bi-est / Tri-est compounded combinations (with estradiol)
NOT FDA-approved in US — only compounding pharmacies (503A/503B)

Who it's for

Estradiol

Moderate-to-severe vasomotor symptoms (hot flashes, night sweats)
Bone density preservation post-menopause
Women under 60 within 10 years of menopause onset
Genitourinary syndrome of menopause (local vaginal estradiol)

Estriol

Vaginal atrophy in women avoiding systemic estrogen
Patients preferring "weakest effective dose" approach
Bi-est combinations preferred by integrative/functional medicine
Patients accepting cash-pay + compounding pharmacy variability

Who should avoid

Estradiol

History of estrogen-receptor-positive breast cancer
Active or recent VTE/PE/stroke
Undiagnosed vaginal bleeding
Active liver disease

Estriol

Patients needing FDA-approved + insurance-covered options
Anyone requiring systemic HRT for bone/CV protection
Patients without access to reputable compounding pharmacy

Side effects

Estradiol

Breast tenderness (most common, ~15%)
Headaches, especially during oral route
Spotting/bleeding (first 3-6 months)
Increased VTE risk (oral > transdermal)
Endometrial hyperplasia if unopposed (requires progesterone with uterus)
Slightly elevated breast cancer risk with combination HRT (WHI data)

Estriol

Local irritation (vaginal cream)
Minimal systemic effects at standard dose
Theoretical endometrial risk (lower than estradiol)
Quality control varies by compounding pharmacy
Insurance rarely covers (cash-pay typical)

Common questions(4)

Is estriol safer than estradiol?

Not necessarily. Estriol is weaker, so systemic exposure is lower, but it is not FDA-approved in the US and quality varies by compounding pharmacy. For bone and cardiovascular protection, estradiol has decades of safety + efficacy data. For local vaginal atrophy alone, either works — local estradiol cream (Estrace) is FDA-approved and insurance-covered.

Can I take estriol if I have a history of breast cancer?

Discuss with your oncologist. Some integrative practitioners prescribe topical estriol for vaginal symptoms in breast cancer survivors, but evidence is limited. The NAMS position is that any estrogen post-breast-cancer requires shared decision-making with the oncology team.

Why is estriol not FDA-approved in the US?

No manufacturer has submitted estriol for FDA approval — the market is small and dominated by compounded products. Estriol IS approved in Europe (Ovestin, Synapause). US patients access it only via 503A/503B compounding pharmacies.

Is bi-est (estradiol + estriol) better than estradiol alone?

No clinical evidence supports bi-est over estradiol alone for menopausal symptoms or bone protection. NAMS and the Endocrine Society do not recommend compounded bi-est. If you prefer the "weaker estrogen" philosophy, low-dose transdermal estradiol achieves the same exposure profile with FDA oversight.

Sources(6)

Peer-reviewed and regulatory references. External links open in new tab.